Triple-Drug attack shows promise for tough stomach cancer
NCT ID NCT04757363
First seen Mar 20, 2026 · Last updated Apr 29, 2026 · Updated 6 times
Summary
This study tests whether combining three drugs—nivolumab (an immunotherapy), FOLFOX (standard chemo), and regorafenib (a targeted therapy)—can safely control HER2-negative metastatic esophagogastric cancer. About 39 adults with advanced disease that has spread will receive this combination. The goal is to see if the mix keeps cancer from growing for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack (All Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, 10604, United States
Conditions
Explore the condition pages connected to this study.